Super-high-dose methylprednisolone does not improve efficacy or induce glucocorticoid resistance in experimental allergic encephalomyelitis.
Neuroimmunomodulation
; 18(1): 28-36, 2011.
Article
in En
| MEDLINE
| ID: mdl-20616573
ABSTRACT
OBJECTIVE:
To investigate whether a super-high dose (SHD) of methylprednisolone (MP) improves its efficacy or induces glucocorticoid (GC) resistance, and to explore the potential mechanisms of GC resistance in experimental allergic encephalomyelitis (EAE).METHODS:
The therapeutic effects of SHD and low-dose MP were evaluated in EAE by analyzing clinical scores, pathological changes and cytokine production. Immunohistochemistry and RT-PCR were used to investigate the expression of GC receptor (GR) isoforms and splicing factor SRp30c.RESULTS:
Both MP doses had similar therapeutic effects. The ratio of GRα to GRß was positively correlated with clinical score changes. However, there was no difference in the GRα/GRß ratio between SHD and low-dose MP groups. SRp30c mRNA was correlated with GRß expression.CONCLUSION:
This study indicates that the GRα/GRß ratio is associated with GC sensitivity, and SRp30c may play an important role in promoting alternative splicing of GR pre-mRNA to generate GRß in EAE rats. Compared with low-dose MP, SHD MP does not improve efficacy or induce GC resistance.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drug Resistance
/
Methylprednisolone
/
Encephalomyelitis, Autoimmune, Experimental
Limits:
Animals
Language:
En
Journal:
Neuroimmunomodulation
Journal subject:
ALERGIA E IMUNOLOGIA
/
NEUROLOGIA
Year:
2011
Document type:
Article
Affiliation country:
China